FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy By Ogkologos - July 1, 2026 32 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CADENZA study Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Postoperative Radioiodine Can Be Avoided in Patients with Low-Risk Differentiated Thyroid... August 12, 2025 New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 What Is Intuitive Eating and How Can It Help During Cancer? January 31, 2023 Load more HOT NEWS ¿Puede una biopsia hacer que mi cáncer se disemine? A More Treatable Kind of Metastatic Cancer? Talking About Sexual Health Concerns With Your Cancer Care Team: How... Reused, Reheated Cooking Oil May Trigger Breast Cancer Progression, Metastasis
